Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life

References

• Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170:3528–33. doi:10.4049/jimmunol.170.7.3528.
   PubMed Web of Science ®Google Scholar
• Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372:379–83. doi:10.1038/372379a0.
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591–604. doi:10.1074/jbc.M009483200.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514–24. doi:10.1074/jbc.M604292200.
   PubMed Web of Science ®Google Scholar
• Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol. 1976;71:666–69. doi:10.1083/jcb.71.2.666.
   PubMed Web of Science ®Google Scholar
• Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol. 1997;158:2211–17.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3:422–30. doi:10.4161/mabs.3.5.16983.
   PubMed Web of Science ®Google Scholar
• Latvala S, Jacobsen B, Otteneder MB, Herrmann A, Kronenberg S. Distribution of FcRn Across Species and Tissues. J Histochem Cytochem. 2017;65:321–33. doi:10.1369/0022155417705095.
   PubMed Web of Science ®Google Scholar
• Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol. 2003;15:187–95. doi:10.1093/intimm/dxg008.
   PubMed Web of Science ®Google Scholar
• Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol. 2007;179:4580–88. doi:10.4049/jimmunol.179.7.4580.
   PubMed Web of Science ®Google Scholar
• Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002;169:5171–80.
   Google Scholar
• Maeda A, Iwayanagi Y, Haraya K, Tachibana T, Nakamura G, Nambu T, Esaki K, Hattori K, Igawa T. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs 2017:9:844–53.
   Google Scholar
• Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006;18:1759–69.
   Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010;28:157–9.
   Google Scholar
• Ober SWED, TX, US. Immunoglobulin molecules with improved characteristics. Austin (TX, US): United States: The Board of Regents of the University of Texas System; 2012.
   Google Scholar
• Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23:1283–88. doi:10.1038/nbt1143.
   PubMed Web of Science ®Google Scholar
• Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011;39:14697–77.
   Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos. 2007;35:86–94. doi:10.1124/dmd.106.011734.
   PubMed Web of Science ®Google Scholar
• Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol. 2006;176:346–56. doi:10.4049/jimmunol.176.6.3635.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem. 2007;282:1709–17. doi:10.1074/jbc.M607161200.
   PubMed Web of Science ®Google Scholar
• Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9:eaaj1928. doi:10.1126/scitranslmed.aaj1928.
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs. 2015;7:331–43. doi:10.1080/19420862.2015.1008353.
   PubMed Web of Science ®Google Scholar
• Huang X, Zheng F, Zhan CG. Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations. Mol Biosyst. 2013;9:3047–58. doi:10.1039/c3mb70231f.
   PubMedGoogle Scholar
• Rabia LA, Desai AA, Jhajj HS, Tessier PM. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. Biochemical Engineering Journal. 2018;137:365–74. doi:10.1016/j.bej.2018.06.003.
   PubMed Web of Science ®Google Scholar
• Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs. 2011;3:568–76. doi:10.4161/mabs.3.6.17922.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21:2153–63. doi:10.1021/bc100261d.
   PubMed Web of Science ®Google Scholar
• Araujo J, Zocher M, Wallace K, Peng K, Fischer SK. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. J Pharm Biomed Anal. 2011;55:1041–49. doi:10.1016/j.jpba.2011.03.008.
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A. 2006;103:18709–14. doi:10.1073/pnas.0606304103.
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall’acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol. 2009;46:1750–55. doi:10.1016/j.molimm.2008.12.022.
   PubMed Web of Science ®Google Scholar
• Young L, Jernigan RL, Covell DG. A role for surface hydrophobicity in protein-protein recognition. Protein Sci. 1994;3:717–29. doi:10.1002/pro.5560030613.
   PubMed Web of Science ®Google Scholar
• Moreira IS, Fernandes PA, Ramos MJ. Hot spots–a review of the protein-protein interface determinant amino-acid residues. Proteins. 2007;68:803–12. doi:10.1002/prot.21474.
   PubMed Web of Science ®Google Scholar
• Lichtarge O, Bourne HR, Cohen FE. An evolutionary trace method defines binding surfaces common to protein families. J Mol Biol. 1996;257:342–58. doi:10.1006/jmbi.1996.0158.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10:244–55. doi:10.1080/19420862.2017.1417718.
   PubMed Web of Science ®Google Scholar
• Caaveiro JM, Kiyoshi M, Tsumoto K. Structural analysis of Fc/FcgammaR complexes: a blueprint for antibody design. Immunol Rev. 2015;268:201–21. doi:10.1111/imr.12365.
   PubMed Web of Science ®Google Scholar
• Levin D, Golding B, Strome SE, Sauna ZE. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol. 2015;33:27–34. doi:10.1016/j.tibtech.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–37. doi:10.1038/nrd.2016.268.
   PubMed Web of Science ®Google Scholar
• Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol. 2010;150:9–20.
   PubMed Web of Science ®Google Scholar
• Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, Kamphaus GD, Fraley C, Zhang Y, Dumont JA, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc Natl Acad Sci U S A. 2008;105:2337–42. doi:10.1073/pnas.0708960105.
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Tiffany MR, Szoka FC. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A. 2012;109:16095–100. doi:10.1073/pnas.1208857109.
   PubMed Web of Science ®Google Scholar
• Cantante C, Lourenco S, Morais M, Leandro J, Gano L, Silva N, Leandro P, Serrano M, Henriques AO, Andre A, et al. Albumin-binding domain from streptococcus zooepidemicus protein zag as a novel strategy to improve the half-life of therapeutic proteins. J Biotechnol. 2017;253:23–33. doi:10.1016/j.jbiotec.2017.05.017.
   PubMed Web of Science ®Google Scholar
• Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry. 2006;45:4983–90. doi:10.1021/bi052628y.
   PubMed Web of Science ®Google Scholar
• Stracke J, Emrich T, Rueger P, Schlothauer T, Kling L, Knaupp A, Hertenberger H, Wolfert A, Spick C, Lau W, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. MAbs. 2014;6:1229–42. doi:10.4161/mabs.29601.
   PubMed Web of Science ®Google Scholar
• Swiercz R, Chiguru S, Tahmasbi A, Ramezani SM, Hao G, Challa DK, Lewis MA, Kulkarni PV, Sun X, Ober RJ, et al. Use of Fc-engineered antibodies as clearing agents to increase contrast during PET. J Nucl Med. 2014;55:1204–07. doi:10.2967/jnumed.113.136481.
   PubMed Web of Science ®Google Scholar
• Patel DA, Puig-Canto A, Challa DK, Perez Montoyo H, Ober RJ, Ward ES. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol. 2011;187:1015–22. doi:10.4049/jimmunol.1100967.
   PubMed Web of Science ®Google Scholar
• Li X, Kimberly RP. Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets. 2014;18:335–50. doi:10.1517/14728222.2014.877891.
   PubMed Web of Science ®Google Scholar
• Devanaboyina SC, Khare P, Challa DK, Ober RJ, Ward ES. Engineered clearing agents for the selective depletion of antigen-specific antibodies. Nat Commun. 2017;8:15314. doi:10.1038/ncomms15314.
   PubMed Web of Science ®Google Scholar